Can a cannabis-based medicine applied to a nonhealing wound improve healing and reduce pain?

| Submission date 08/03/2020 | Recruitment status No longer recruiting | Prospectively registered | | |
|-----------------------------------|---|--|--|--|
| | | ☐ Protocol | | |
| Registration date 10/03/2020 | Overall study status Completed | Statistical analysis plan | | |
| | | [X] Results | | |
| Last Edited 19/05/2023 | Condition category Skin and Connective Tissue Diseases | [] Individual participant data | | |

Plain English summary of protocol

Background and study aims

Wound healing is a serious problem worldwide. Non-healing wounds lead to reduced quality of life, limb amputation, increased death rates, and losses in human productivity. They can also lead to increased opioid use (and potential addiction) and antibiotic resistance. In the USA, nearly \$100 billion is spent each year on on wound-related treatments, mostly on dressings that do not treat the underlying medical problems that stop the wound healing.

Wounds that do not heal are stalled in a state of extreme inflammation. The cannabis plant contains several types of anti-inflammatory chemicals. These include cannabinoids, which have been shown to reduce inflammation and enable the wound healing process to progress, as well as flavonoids and terpenes that also have positive effects on wound healing.

This study aims to investigate a topical medicine (meaning one that is applied directly to the site of the disease) based on cannabis in wounds that have not healed for 6 months or more. The treatment will be applied to the wound and around the wound. The effects on healing and pain will be measured.

Who can participate?

Adults with non-healing, deep wounds that have not healed for at least 6 months despite treatment

What does the study involve?

Participants will apply the medicine to the wound and around the wound once a day until it has healed.

What are the possible benefits and risks of participating?

There are not thought to be any side effects from the cannabis-derived ingredients of the medicine. The medicine acts at the site of the wound and is not distributed around the body to a significant extent. However, there is a small risk that application of the medicine might introduce infection into the wound.

The potential benefits are that the medicine might stimulate wound healing or reduce pain.

Where is the study run from? William Osler Health System (Canada)

When is the study starting and how long is it expected to run for? May 2018 to June 2019

Who is funding the study? VinSan Therapeutics Inc (Canada), which produces the cannabis-based medicine

Who is the main contact?

Dr Vincent Maida, vintordoc@icloud.com

Contact information

Type(s)

Public

Contact name

Dr Vincent Maida

ORCID ID

https://orcid.org/0000-0002-8693-0617

Contact details

Palliative Care Unit 9th Floor 101 Humber College Boulevard Toronto Canada L4L 7B2 +1 416-346-6829 vintordoc@icloud.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Nil known

Study information

Scientific Title

Topical cannabis-based medicines for wound healing and pain management

Study objectives

Integumentary wounds are states of dysregulation within the endogenous cannabinoid system (ECS). Topical cannabis-based medicines (TCBM), composed of proprietary mixtures of cannabinoids, terpenes, and flavonoids, are postulated to interact with the multiple elements of the ECS, and other signalling systems to restore homeostasis and thus promote integumentary wound healing and relieve wound-related pain. TCBM is applied to both the wound bed and the peri-wound integument as ECS dysregulation is present in both areas.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 06/06/2018, William Osler Health System Research Ethics Board (Room S.3.907, 2100 Bovaird Drive East, Brampton, Ontario, L6R 3J7, Canada; +1 (905) 494-2120 x50448; Michelle. Dimas@williamoslerhs.ca), ref: 18-0038

Study design

Prospective open-label serial case series

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Intractable non-healing wounds afflicting patients with vasculitic and vasculopathic disorders

Interventions

A thin layer of VinSan was applied topically to both the wound bed and peri-wound integumentary tissues (approximately a 2-5 cm cuff around the wound bed) daily until complete wound closure.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

VinSan topical cannabis-based medicines

Primary outcome(s)

Time to complete wound closure as reported by participants or family members

Key secondary outcome(s))

- 1. Wound-related pain assessed in terms of analgesic use in daily milligram morphine equivalents (MME)
- 2. Wound size (longest length x widest width in cm2) measured at each clinic or home visit by the investigator or their delegate

Completion date

Eligibility

Key inclusion criteria

Intractable, non-healing integumentary wounds of more than 6 months duration that have failed best practices and evidence-based medical treatments

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

42

Key exclusion criteria

- 1. Declined to sign informed consent
- 2. Reported a prior misadventure with cannabis
- 3. Allergy to cannabis

Date of first enrolment

06/06/2018

Date of final enrolment

10/05/2019

Locations

Countries of recruitment

Canada

Study participating centre Etobicoke General Hospital

101 Humber College Boulevard Toronto Canada M9V 1R8

Sponsor information

Organisation

William Osler Health System

ROR

https://ror.org/03d1xjg58

Funder(s)

Funder type

Industry

Funder Name

VinSan Therapeutics Inc

Results and Publications

Individual participant data (IPD) sharing plan

The anonymized data in Excel files is available on request from Dr Vincent Maida (vintordoc@icloud.com).

IPD sharing plan summary

Available on request

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|-------------------------------|-------------------------------|--------------|------------|----------------|-----------------|
| Results article | | 01/09/2021 | 29/03/2022 | Yes | No |
| Basic results | | 17/07/2020 | 17/07/2020 | No | No |
| Other files | Case study of 2 participants | 02/09/2020 | 19/05/2023 | No | No |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |